Lillian M. Guenther

Dysregulated AKT signaling reprograms osteosarcoma to drive selective reliance on EP300

Here, Delahunty et al. identify that EP300 controls the growth of AKT-dysregulated osteosarcoma cells by regulating expression of state-specific genetic dependencies. AKT inhibitors synergize with EP300 degraders to suppress osteosarcoma growth in vitro and in vivo. These agents positively combine across cancer cells i...